Related Experiment Video

Updated: Jan 24, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.4K

Efficacy of tofacitinib treatment in ulcerative colitis

Julián Panés1, Javier P Gisbert2

  • 1Servei de Gastroenterología, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, España.

Gastroenterologia Y Hepatologia
|May 19, 2019
PubMed

Insights

Tofacitinib, a Janus kinase inhibitor, offers a new oral treatment for ulcerative colitis. Clinical trials confirm its efficacy and safety, leading to European approval for managing this inflammatory bowel disease.

Area of Science:

  • Gastroenterology and Immunology
  • Pharmacology and Therapeutics

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Current treatments have limitations, necessitating novel therapeutic options.
  • Janus kinases (JAKs) play a crucial role in UC pathogenesis.

Purpose of the Study:

  • To review the characteristics of tofacitinib, an oral JAK inhibitor.
  • To compare tofacitinib with existing biological agents for UC.
  • To discuss the clinical efficacy, safety, and optimal use of tofacitinib in UC.

Main Methods:

  • Review of clinical trial data on tofacitinib in moderate to severe UC.
  • Analysis of tofacitinib's mechanism of action as a JAK inhibitor.
  • Comparative assessment against biological therapies for UC.

Main Results:

  • Tofacitinib demonstrated significant efficacy and a favorable safety profile in clinical trials for UC.
  • The drug offers an oral alternative to parenteral biological agents.
  • European Medicines Agency approval signifies its recognized therapeutic value.

Conclusions:

  • Tofacitinib represents a significant advancement in UC treatment.
  • It provides a valuable oral therapeutic option for patients with moderate to severe UC.
  • Understanding its optimal use is key for effective clinical management.
Keywords:
Cinasas JanusColitis ulcerosaEfficacyEficaciaJanus kinasesTofacitinibUlcerative colitis

More Related Videos

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.5K
Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System15:49

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System

Published on: October 16, 2013

32.6K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
482
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
941
Self-Efficacy01:29

Self-Efficacy

Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
211
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.0K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
763
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
457